Brokerages Set Edwards Lifesciences Corporation (NYSE:EW) Price Target at $100.27

Shares of Edwards Lifesciences Corporation (NYSE:EW) have earned a consensus recommendation of “Moderate Buy” from the twenty-three brokerages that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $100.2727.

Several research firms have recently weighed in on EW. BTIG Research boosted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. JPMorgan Chase & Co. raised their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Royal Bank Of Canada lifted their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Barclays reiterated an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 26,190 shares of company stock valued at $2,269,697 in the last ninety days. 0.31% of the stock is owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently modified their holdings of the business. L2 Asset Management LLC purchased a new stake in Edwards Lifesciences in the second quarter worth $315,000. Paradigm Capital Management Inc. NY purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at $398,000. Aberdeen Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at $159,000. Ally Financial Inc. bought a new position in shares of Edwards Lifesciences in the second quarter worth about $2,352,000. Finally, Cibc World Market Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter worth about $3,595,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Down 0.4%

Shares of NYSE:EW opened at $92.64 on Friday. The company has a market cap of $53.34 billion, a price-to-earnings ratio of 53.24, a PEG ratio of 2.34 and a beta of 0.85. Edwards Lifesciences has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $88.62 and a 200 day moving average price of $84.32.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same period in the previous year, the firm posted $0.67 earnings per share. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts predict that Edwards Lifesciences will post 3 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.